Indeed, Bcr-Abl1 tyrosine kinase modifies the actin structure and cytoskeleton function (65), probably also by actin adaptors, such as FAK, whose codifying gene is expressed at a very low level in CML, especially in advanced phases of the disease (66). The gene discussed is PTK2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.